CloudMD Software & Services (CSE: DOC) announced this morning that it is moving forward with its plan to install kiosks in pharmacies across Canada. The kiosks will enable patients to have access to on-demand telemedicine visits with licensed doctors.
The service is novel in that it enables patients to renew expired prescriptions while on site at the pharmacy, resulting in better continuity of care. Often, patients arrive at pharmacies to acquire a refill only to find out that the prescription has expired or that there are no remaining refills left. With the implementation of an in pharmacy kiosk, the patient will be able to renew the prescription quickly while preventing a disruption of care.
The kiosks are to be implemented in existing private consult rooms currently maintained by pharmacies across Canada. Patients will be able to see a licensed doctor quickly for the purpose of prescription refills or that of non-emergency health concerns via a telemedicine visit, with the resulting prescription then being eFaxed to the pharmacy directly for fulfillment.
We’re excited to be able to bring this innovative care option to patients. The local pharmacist is an important part of a patient’s allied healthcare team. Unfortunately many patients don’t find out they are out of refills until they are at the pharmacy and are unable to get a new prescription before they run out. At CloudMD, we are committed to providing patients access to the care they need, when they need it. Through this new telehealth offering, patients now have an additional option for seeking care that is even more convenient for them.
Dr. Essam Hamza, CEO of CloudMD
Further updates from participating pharmacies are expected to occur as they sign on to using the service.
Sponsored · Altamira Gold Corp.
CloudMD Software & Services last traded at $0.54 on the CSE.
FULL DISCLOSURE: CloudMD Software & Services is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover CloudMD Software & Services on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
